STOCK TITAN

ImmunityBio Inc - IBRX STOCK NEWS

Welcome to our dedicated news page for ImmunityBio (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunityBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunityBio's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
ImmunityBio Inc

OTC:IBRX

IBRX Rankings

IBRX Stock Data

3.68B
142.88M
79.62%
8.86%
7.69%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About IBRX

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.